Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 37, Issue -, Pages S86-S103Publisher
SPRINGER
DOI: 10.1007/s00259-010-1503-4
Keywords
Angiogenesis; Vascular endothelial growth factor; Fibronectin ED-B domain; Integrin alpha(v)beta(3); Matrix metalloproteinase; Imaging; Positron emission tomography
Funding
- Intramural NIH HHS [ZIA EB000073-01, Z99 EB999999] Funding Source: Medline
Ask authors/readers for more resources
Position emission tomography imaging of angiogenesis may provide non-invasive insights into the corresponding molecular processes and may be applied for individualized treatment planning of antiangiogenic therapies. At the moment, most strategies are focusing on the development of radiolabelled proteins and antibody formats targeting VEGF and its receptor or the ED-B domain of a fibronectin isoform as well as radiolabelled matrix metalloproteinase inhibitors or alpha(v)beta(3) integrin antagonists. Great efforts are being made to develop suitable tracers for different target structures. All of the major strategies focusing on the development of radiolabelled compounds for use with positron emission tomography are summarized in this review. However, because the most intensive work is concentrated on the development of radiolabelled RGD peptides for imaging alpha(v)beta(3) expression, which has successfully made its way from bench to bedside, these developments are especially emphasized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available